StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)

Investment analysts at StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIMGet Rating) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright increased their price objective on Alimera Sciences from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th.

Alimera Sciences Stock Up 4.2 %

Shares of NASDAQ:ALIM opened at $4.98 on Friday. Alimera Sciences has a 52-week low of $3.94 and a 52-week high of $7.92. The stock has a market cap of $34.86 million, a P/E ratio of -2.00 and a beta of 1.38. The business’s 50 day moving average is $5.61 and its 200 day moving average is $5.72.

Institutional Trading of Alimera Sciences

An institutional investor recently bought a new position in Alimera Sciences stock. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Alimera Sciences, Inc. (NASDAQ:ALIMGet Rating) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,400,000. Healthcare of Ontario Pension Plan Trust Fund owned 3.58% of Alimera Sciences as of its most recent SEC filing. 34.53% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

(Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

See Also

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.